Candel Therapeutics (CADL) shares climbed by more than 120% in premarket trading after the biopharmaceutical company said a phase 3 trial of CAN-2409 to treat localized prostate cancer met its primary endpoint.
The primary endpoint was to demonstrate a statistically significant improvement in disease-free survival compared to the control arm.
The company said that based on the study's results it plans to begin discussions with the US Food and Drug Administration about a regulatory pathway for CAN-2409 to treat localized prostate cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.